Business
Curis Announces First Patient Dosed in Phase 1/2 Study of CA-4948 Combination Therapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
- Initial data expected in 2022 - LEXINGTON, Mass., Nov. 8, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the
About this update from Curis, Inc.
[{"type":"text","content":"- Initial data expected in 2022 -\n\n\n LEXINGTON, Mass., Nov. 8, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the first patient has been dosed in the combination therapy portion of the Phase 1/2 clinical study evaluating CA-4948, a novel, small molecule IRAK4 kinase inhibitor, in acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS).\n\n \n \n \n \n \n \n\n \n\"We are very pleased to announce the initiation of our Phase 1 combination therapy study of CA-4948, which is an important part of our development strategy to address the broader AML/MDS patient population,\" said James Dentzer, President and Chief Executive Officer of Curis. \"This comes on the heels of the promising initial monotherapy data with CA-4948 in this patient population. Armed with these results and combined with preclinical data highlighting CA-4948's synergistic antitumor activity when used in combination with azacitidine and venetoclax, and the absence of overlapping dose-limiting toxicity, we are hopeful that this combination portion of the trial will allow us to advance CA-4948 as a promising new treatment for an additional population of patients with AML/MDS.\"\n\"Based on CA-4948's initial efficacy and tolerability in monotherapy, we are looking forward to exploring safety and efficacy for CA-4948 in combination with azacitidine or venetoclax,\" said Dr. Stefano Tarantolo, M.D., hematologist and oncologist at Nebraska Cancer Specialists and a leading investigator on the study. \"We are hopeful that CA-4948 may offer an important new treatment option, as many of these patients are ineligible for intensive chemotherapy and face an extremely poor prognosis.\" \nAbout the CA-4948 Phase 1/2 Study in Patients with AML/MDS\nThe Phase 1/2 study was expanded to include both a monotherapy dose expansion and a combination dose escalation. The monotherapy portion of the study includes R/R MDS patients with and without a spliceosome mutation and R/R AML patients with and without a FLT3 mutation. The combination therapy portion of the study includes two arms: CA-4948 plus azacitidine, for patients naïve to HMA, and CA-4948 plus venetoclax, for patients naïve to venetoclax. \nWhen combined with azacitidine, CA-4948 wil...